Sudeep Pharma Ltd. has filed its preliminary papers with the Securities and Exchange Board of India to raise funds via an initial public offering.
The public offer will include a mix of fresh issues of shares worth Rs 95 crore and an offer for sale of 1 crore shares by existing shareholders, according to the draft red herring prospectus that was filed on Tuesday.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Sujit Jaysukh Bhayani, Sujeet Jaysukh Bhayani HUF, Shanil Sujit Bhayani and Avani Sujit Bhayani are the promoter selling shareholders offloading stakes in the OFS segment.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
ICICI Securities Ltd. and IIFL Capital Services Ltd. are the book-running lead managers for the issue and MUFG Intime India Pvt. will be the registrar of the issue.
The proceeds from the fresh issue will be utilised for capital expenditure towards procurement of machinery for the company's production line located at Nandesari facility.
The equity shares are proposed to be listed on the National Stock Exchange of India and BSE Ltd.
About Sudeep Pharma
Sudeep Pharma is a technology-driven manufacturer specialising in excipients and specialty ingredients for the pharmaceutical, food and nutrition industries. The company has developed technologies, including encapsulation, spray drying and granulation.
With a significant global footprint, Sudeep Pharma serves markets across the US, South America, Europe, West Asia, Africa and Asia-Pacific. As per the DRHP, the company is recognised as one of the largest producers of food-grade iron phosphate, which is widely used in infant nutrition, clinical nutrition, and the food and beverage sectors.
Sudeep Pharma Financials
Sudeep Pharma's revenue from operations increased 14% to Rs 459.2 crore in fiscal 2024 from Rs 428.7 crore in fiscal 2023. Profit for the period more than doubled to Rs 133 crore for the financial year ended March 2024 as compared to Rs 62.3 crore in the year-ago period.
As of April 30, 2025, the company's debt pile stood at Rs 110.3 crore.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
